SPRB

About SPRB

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The Company is also developing Tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. The Company has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with poor disease control and anticipate topline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH with good disease control focused on glucocorticoid reduction and anticipate topline.

Buy US stocks in Australia with $0 brokerage and trade SPRB today!